Healthpeak Properties Inc (DOC)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Healthpeak Properties Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 21.60 $ — 83% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/04/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
Quality & Screener
AAQS
2/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% 3.2%
- Exp. sales growth 3Y > 5% 2.5%
- EBIT growth 10Y > 5% -3.1%
- Exp. EBIT growth 3Y > 5% 2.5%
- Net debt < 4x EBIT 18.2x
- EBIT positive, 10Y straight 10
- Max. EBIT decline < 50% 70.1%
- Return on equity > 15% 1.1%
- ROCE > 15% 2.8%
- Expected return > 10% 11.0%
View all AAQS quality stocks · Read the methodology at AlleAktien
Source: fundamental data
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
2 of 10 Weak growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 11.0% failed
- More than 10% revenue growth is expected for the coming year 3.5% failed
- Share count grows by less than 3% a year 8.9% failed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 44.1% passed
- Gross margin at 40% or higher and without meaningful erosion 22.5% failed
- Goodwill from acquisitions does not grow faster than revenue 0.3% failed
- Net debt below twice EBITDA 6.7 x EBITDA failed
- Operating cash flow covers the profits of the last three years 2,658 m passed
- Return on capital at 15% or higher, or up versus two years ago 2.8% failed
- Insiders hold at least 10% or are net buyers 0.3% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 3.7% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 20
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 0.41 | 0.26 – 0.55 | 2,869 | 938.5% | 2 |
| 12/31/2027 | -0.15 | -0.15 – -0.15 | 2,963 | -137.0% | 1 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- 0.44 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 0.01 | -95.00 | 698 | 26.10 | 0.70 | 284 | 284 |
| 2025: Q1 | 0.06 | 451.70 | 703 | 15.90 | 6.10 | 279 | 279 |
| 2025: Q2 | 0.05 | -78.10 | 694 | -0.20 | 4.60 | 364 | 364 |
| 2025: Q3 | -0.17 | -237.10 | 706 | 0.80 | -16.60 | 315 | 288 |
| 2025: Q4 | 0.16 | 2,419.20 | 719 | 3.10 | 15.80 | 294 | 294 |
| 2026: Q1 | 0.28 | 354.70 | 753 | 7.10 | 25.70 | 261 | 237 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 2,129 | 719 | 628 | 4.81 | 1,214 | 1,809 | 2,888 |
| 2017 | 1,848 | 559 | 414 | 2.46 | 847 | 2,560 | 4,164 |
| 2018 | 1,191 | 311 | 1,061 | 5.66 | 849 | 2,472 | 4,143 |
| 2019 | 1,240 | 307 | 46 | 0.09 | 846 | 2,509 | 4,347 |
| 2020 | 1,645 | 215 | 414 | 0.78 | 758 | 6,734 | 15,920 |
| 2021 | 1,896 | 340 | 506 | 0.94 | 795 | 6,515 | 15,258 |
| 2022 | 2,061 | 357 | 500 | 0.93 | 900 | 6,655 | 15,771 |
| 2023 | 2,181 | 434 | 306 | 0.56 | 956 | 6,350 | 15,699 |
| 2024 | 2,700 | 471 | 243 | 0.36 | 1,071 | 8,401 | 19,938 |
| 2025 | 2,823 | 544 | 71 | 0.10 | 1,252 | 7,500 | 20,336 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Healthpeak Properties, Inc. ist ein S&P-500-Unternehmen, das hochwertige Immobilien mit Fokus auf Gesundheitsforschung und -versorgung in den USA besitzt, betreibt und entwickelt.
| CEO Insider Trades (12 Mo.) | buying own stock |
|---|---|
| Employees | 411 |
| Headquarters | Denver, CO |
| Address | 4600 South Syracuse Street, 80237 Denver, United States |
| Phone | (720) 428-5050 |
| Website | healthpeak.com |
| IPO Date | 5. Nov 1987 |
| ISIN | US42250P1030 |
| Stock Split | 1098:1000 on 11/01/2016 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Scott M. Brinker | President, CEO & Director | 1977 |
| Kelvin O. Moses | Chief Financial Officer | 1989 |
| Adam G. Mabry | Chief Investment Officer | 1985 |
| Tracy A. Porter | Executive VP, General Counsel & ESG | 1978 |
| Scott R. Bohn | Chief Development Officer & Head of Lab | 1980 |
| Shawn G. Johnston | Executive VP & Chief Accounting Officer | 1980 |
| Andrew Johns CFA | Senior Vice President of Investor Relations | – |
| James A. Croy | Senior Vice President of Leasing - Outpatient Medical | – |
| Michelle Wood | Senior VP, CFO and Controller of Senior Housing & Lab | – |
| R. Justin Hill | Senior Vice President of Outpatient Medical | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.